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Abstract
Background & Aims: Health-related quality of life (HRQoL) is impaired in patients with
Inflammatory Bowel Disease (IBD). The aim was prospectively to assess and validate the pattern
of HRQoL in an unselected, population-based inception cohort of IBD patients from Eastern and
Western Europe.
Methods: The EpiCom inception cohort consists of 1560 IBD patients from 31 European centres
covering a background population of approximately 10.1 million. Patients answered the disease
specific Short Inflammatory Bowel Disease Questionnaire (SIBDQ) and generic Short Form 12
(SF-12) questionnaire at diagnosis and after one year of follow-up.
Results: In total, 1079 patients were included in this study. Crohn's disease (CD) patients mean
SIBDQ scores improved from 45.3 to 55.3 in Eastern Europe and from 44.9 to 53.6 in Western
Europe. SIBDQ scores for ulcerative colitis (UC) patients improved from 44.9 to 57.4 and from
48.8 to 55.7, respectively. UC patients needing surgery or biologicals had lower SIBDQ scores
before and after compared to the rest, while biological therapy improved SIBDQ scores in CD. CD
and UC patients in both regions improved all SF-12 scores. Only Eastern European UC patients
achieved SF-12 summary scores equal to or above the normal population.
1032 J. Burisch et al.Conclusion: Medical and surgical treatment improved HRQoL during the first year of disease.
The majority of IBD patients in both Eastern and Western Europe reported a positive perception
of disease-specific but not generic HRQoL. Biological therapy improved HRQoL in CD patients,
while UC patients in need of surgery or biological therapy experienced lower perceptions of
HRQoL than the rest.
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 1. Introduction
Crohn's disease (CD) and ulcerative colitis (UC) affect patients
not only physically but also through limitations on social,
educational, professional, and emotional activities due to
chronicity, unpredictable disease course, young age of onset
and their medical and surgical therapies. Patients with
Inflammatory Bowel Disease (IBD) experience an impaired
perception of health-related quality of life (HRQoL) compared
with a healthy background population,1–4 with disease course
and disease activity,5,6 the perceived quality of care deliv-
ered, and the individual's psychological status and social
support7,8 as important factors affecting HRQoL. Data on
HRQoL from unselected population-based cohorts are limited
as most studies are based on selected cohorts or phase III
trials9,10 of varying design, prohibiting generalisations about
the IBD patient population.11 However, population-based
unselected cohorts including mild-to-severe cases offer the
most accurate picture of community effectiveness regarding
therapeutic approaches for IBD patients and the impact of
these approaches on HRQoL.
The European Crohn's and Colitis Organization's (ECCO)
Epidemiological Committee (EpiCom) study is a prospective-
ly collected unselected population-based inception cohort of
1560 IBD patients, recruited from 31 medical centres from
Eastern and Western Europe. Previously, the group demon-
strated a two-to-one West–East incidence gradient in
Europe with incidences correlating with the GDP of each
country.12 IBD patients in Eastern and Western Europe were
not different regarding socio-demographic and disease
related characteristics as well as disease course but regional
differences in treatment choices during the initial year of
disease were found i.e. in the use of biological agents and
5-ASA for CD and UC patients.13,14 The aim of this study was
therefore to investigate the differences in HRQoL at
diagnosis and after the initial year of disease, across Eastern
and Western Europe and, to assess the impact of treatment
choices on HRQoL.2. Materials and methods
2.1. Study population
The EpiCom-cohort is a population-based prospective incep-
tion cohort of incident IBD patients established through
collaboration amongst 31 medical centres from 8 Eastern and
14 Western European countries covering a total background
population of 10.1 million inhabitants (3.3 million in Eastern
and 6.8 million in Western Europe). A total of 1560 incident
IBD patients (550 with CD, 840 with UC and 170 withInflammatory Bowel Disease Unclassified (IBDU)) diagnosed
between 1 January and 31 December 2010, and living in the
predefined catchment areas at the time of diagnosis, were
prospectively included in the EpiCom cohort and followed up
annually starting in 2010. Standardised methods for case
ascertainment, diagnostic criteria for case definition, time
period of inclusion and recorded patient data were used. One
centre from Eastern Europe included only patients aged
b15 years at diagnosis and did not take part in the HRQoL
assessment of patients as only adult patients were included in
the present study.
2.2. Classifications and definitions
The diagnosis of CD, UC or IBDU was based on the
Copenhagen Diagnostic Criteria.15–17 Disease extent for
UC, as well as disease location and behaviour for CD, were
defined according to the Montreal Classification.18 Medical
treatment was grouped into five treatment groups in
ascending potency of treatment: 5-aminosalicylates (5-ASA)
(oral and/or topical 5-ASA treatment ± topical steroids),
glucocorticosteroids (GCS) (oral steroids ± 5-ASA or topical
steroids), immunomodulators (azathioprine, mercaptopu-
rine, cyclosporine or methotrexate ± steroids), biologicals
(infliximab or adalimumab in combination with any of the
above), and surgery (major abdominal surgery due to IBD
regardless of medical treatment prior to surgery). Immuno-
modulators were combined in one category due to the fact
that 94% of patients received treatment with thiopurines. A
severe disease course in UC was defined as any disease
extent and a need for high dose GCS (0.5–1 mg/kg), and/or
immunomodulators, and/or biologicals, and/or surgery.
Severe CD was defined as the need for immunomodulators,
and/or biologicals, and/or surgery within the first year after
diagnosis.
2.3. Questionnaires
Patient-reported HRQoL was assessed using the Short Inflam-
matory Bowel Disease Questionnaire (SIBDQ) and the Short
Form 12 (SF-12). Validated translations of the questionnaires
were used if available. The SIBDQ is a disease-specific
questionnaire consisting of ten questions covering four
dimensions: bowel, systemic, emotional and social,19 which
has been shown to correlate well with the longer IBDQ
questionnaire.20 The questionnaire is scored on a seven-point
scale with higher scores indicating a better HRQoL. The total
score ranges from 10 (worst health) to 70 (best health). The
SF-12 is a generic HRQoL questionnaire of twelve questions
taken from the Short Form 36 questionnaire,21 which are
grouped into a physical and a mental component summary
1033Health-related quality of life improves during one year of medical and surgical treatment
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 score (PCS and MCS) and eight multi-item scales: Physical
functioning (PF), Role limitation due to physical health (RP),
bodily pain (BP), general health (GH), vitality (VT), social
functioning (SF), role limitations due to emotional problems
(RE), and mental health (MH). The SF-12 scores were
transformed to achieve a mean score of 50 and a standard
deviation of 10 in the 1998 general U.S-population,22 which has
been shown to have a good equivalence with country-specific
scores in ten Western European countries.23,24
2.4. Data collection and assessment of HRQoL
Patients were included in the cohort at diagnosis and followed
prospectively every third month throughout the follow-up
period. Data regarding demographics, disease activity, med-
ical therapy, surgery, blood samples, cancers and deaths was
regularly collected. Data validity was secured by a variety of
measures which have been thoroughly described elsewhere.12
Patient-reported questionnaires were administered twice
during the follow-up period: a) at time of diagnosis or within
a 90-day period, and b) at nine to twenty-four months of
follow-up. This interval was chosen in order to compensate for
variations in follow-up visits due to holidays, weekends and
personal reasons of the patients, and since centres chose to
follow-up patients for either twelve months or until the end of
the year 2011 for local practical reasons. Questionnaires were
administered to participating patients by one of the following
methods: 1) interview conducted by the physician at an
outpatient visit, or 2) self-administrated. All data were
entered by physicians and/or IBD specialist trained nurses in
the web-based inception cohort EpiCom database.25 Validated
translated versions of the questionnaires were available for all
centres except for Greenland, the Faroe Islands and Chisinau,
Moldova where a Danish and Romanian translation, respec-
tively, was used instead.
2.5. Statistical analysis
Statistical analyses were performed using SAS software v.
9.2. Demographics and disease classification between groups
were compared with a Chi-square test. Standard parametric
methods were used to analyse differences in HRQoL scores
between groups. Results for continuous variables are
expressed as median (range) unless otherwise stated, while
scores for questionnaires are expressed as mean (standard
deviation, SD). If more than two questions in the SIBDQ were
missing no total SIBDQ score was calculated; if one or two
questions were missing the total SIBDQ score was rescaled
with 10/9 or 10/8. Dimensions containing missing data were
not calculated. Good HRQoL was defined as a score above 50
points based on results from the IBDQ.26 Responders were
defined as patients experiencing an improved SIBDQ score
from ≤50 at diagnosis to N50 at follow-up. Only completed
SF-12 questionnaires were calculated and included in the
analysis. Changes in mean SIBDQ and SF-12 (PCS and MCS)
scores from diagnosis until the end of follow-up were
analysed using linear normal analysis of covariance
(ANCOVA) while controlling for the effects of gender, type
of diagnosis, geographical region, age at diagnosis, smoking
status, treatment with steroids, employment status, level of
education, extra-intestinal manifestations, disease extent,disease behaviour, severe disease course, as well as surgery,
biological therapy or hospitalization during follow-up. SIBDQ
responders were analysed by logistic regression using the
same set of covariates with backward elimination of
insignificant factors. A p-value of b0.05 was considered
statistically significant.
2.6. Ethical considerations
The study was approved by the relevant ethical committees
according to local regulations. All patients gave informed
consent prior to answering the questionnaires.
3. Results
In total, 1079 (69% of the total cohort) IBD patients aged
15 years or older at diagnosis from 30 study centres answered
the questionnaires, 402 (37%) with CD, 575 (53%) with UC, and
102 (10%) with IBDU. Themajority of patients, 838 (78%), were
diagnosed in Western Europe. A subset of 436 (31%) patients
from the original cohort did not give consent to answer the
questionnaires (288, 64%) or were lost during follow-up (148,
34%) and thus were excluded. In terms of socio-demographic
characteristics and disease course, patients included in the
study only differed in the distribution of diagnosis from the
excluded patients, as the fraction of CD patients was larger
and the fraction of IBDU patients was smaller in the former
group. Patients' demographic characteristics are shown in
Table 1. No difference between the two geographic regions
was seen, with the exception of the highest treatment step
reached during follow-up for CD patients and the educational
status in CD and UC patients.
3.1. SIBDQ
A total of 1071 patients filled out at least one SIBDQ. Of those,
825 (77%) patients answered a SIBDQ at diagnosis and 837
(78%) at follow-up; 591 (55%) patients answered a question-
naire both at diagnosis and at follow-up. The median time to
answering SIBDQ was 0.6 months (range: 0–3) and 14.6 months
(range: 9–24) at diagnosis and follow-up, respectively. The
mean scores for the SIBDQ in Western and Eastern Europe are
shown in Table 2. For CD patients disease-specific HRQoL
improved significantly from 44.9 to 53.6 (p b 0.01) in Western
Europe and from 45.3 to 55.3 (p b 0.01) in Eastern Europe
during follow-up. Likewise, SIBDQ scores for UC patients
improved from 48.8 in Western Europe and 44.9 in Eastern
Europe at diagnosis to 55.7 and 57.4, respectively (p b 0.01). Of
the IBDU patients, only those in Western Europe experienced a
significantly more positive perception of HRQoL, rising from
49.9 to 54.9 (p = 0.01).
In Western Europe, the mean SIBDQ total score was
significantly lower for CD than for UC patients at both
diagnosis (44.9 vs. 48.8, p b 0.01) and at follow-up (53.6 vs.
55.7, p = 0.03). Furthermore, Western European UC patients
had a significantly higher mean SIBDQ score at diagnosis
compared to UC patients in Eastern Europe (48.8 vs. 44.9,
p b 0.01). The proportion of patients with good HRQoL
(SIBDQ total score over 50) improved during follow-up with
the exception of Eastern European IBDU patients (Fig. 1).
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 Overall, the mean SIBDQ scores for all IBD patients improved
in the majority of centres (p b 0.01) (Fig. 2).
During follow-up and prior to completing the last SIBDQ,
36 (9%) CD patients (median time to surgery: 4.9 months,
range: 0–15) and 11 (2%) UC patients (median time to
surgery: 7.7 months, range: 1–13) from Eastern and Western
Europe underwent surgery, while 46 (11%) CD patients
(median time to biologicals: 4.7 months, range: 0–23) and
14 (2%) UC patients (median time to biologicals: 5.5 months,
range: 0–16) received biological therapy and no surgery. UC
patients undergoing surgery or receiving biological therapy
during follow-up had significantly lower mean SIBDQ scores
at both diagnosis and at follow-up compared to UC patients
not undergoing surgery or receiving biological therapy during
follow-up (Fig. 3). For CD patients this was only the case for
patients needing biological therapy during follow-up. The
mean SIBDQ scores significantly improved during follow-up
for both CD (41.6 to 54.4, p b 0.01) and UC patients (37.9 to
49.2, p b 0.01) needing surgery. CD patients treated with
biologicals clinically significantly improved their SIBDQ
scores (40.9 to 52.1, p b 0.01) while the improvement in
UC did not reach significance (37.4 to 45.2, p = 0.22).
A total of 591 (55%) patients were included in the ANCOVA
analysis and responder analysis for SIBDQ. These patients only
differed in terms of smoking status (more patients included in
the analysis where former smokers) from the rest of the study
population. For IBD patients overall (335, 57%) with low HRQoL
at diagnosis, only baseline SIBDQ score (odds ratio (OR) 1.1 CI
95% 1.02–1.08, p b 0.01) predicted achieving good HRQoL
(SIBDQ score N50) at follow-up (Fig. 4). For UC patients this
was the case for baseline SIBDQ score (OR 1.1 CI 95% 1.02–
1.11, p b 0.01), limited disease extent (E1 vs. E2: OR 5.3
CI95% 2.0–14.1; E1 vs. E3: OR 4.9 CI95% 1.8–13.8; p b 0.01),
not receiving biological therapy (no biologicals vs. biologicals:
OR 25.2 CI95% 2.4–259.8, p b 0.01), and not undergoing
surgery during follow-up (no surgery vs. surgery: OR 4.4 CI95%
1.1–18.7, p = 0.03). No significant predicting factors for CD
patients were found. The results of the ANCOVA analysis are
shown in Table 3.e 3, 20163.2. SF-12
In total, 1074 patients answered a SF-12 questionnaire, 830
(77%) at diagnosis and 833 (78%) at follow-up. 589 (55%)
patients answered a questionnaire at both diagnosis and
follow-up. Median time to answering the SF-12 was
0.6 months (range: 0–3) and 14.7 months (range: 9–24) at
diagnosis and follow-up, respectively. The mean scores for
the SF-12 survey are shown in Table 4. CD patients in both
Western and Eastern Europe improved their generic HRQoL
in all eight multi-item scales and both summary scores from
diagnosis to follow-up. In the same way UC patients
improved in both summary scores and all multi-item scales
(Western European UC patients however in all but “general
health”). Only Western European IBDU patients improved in
terms of the vitality item and MCS (Fig. 5). However, only
Eastern European UC and IBDU patients achieved a generic
HRQoL in terms of the two SF-12 summary scores equal to or
higher than the healthy background population (Table 4). A
subset of 589 (55%) patients was included in the ANCOVA
analysis for SF-12; results are shown in Table 3.During follow-up and prior to filling out the last SF-12, a
total number of 36 (9%) CD patients (median time to surgery:
4.9 months, range: 0–15) and 12 (2%) UC patients (median
time to surgery: 8.3 months, range: 1–22) from Eastern and
Western Europe underwent surgery, while 47 (12%) CD
patients (median time to biologicals: 4.4 months, range:
0–23) and 14 UC (2%) patients (median time to biologicals:
5.5 months, range: 0–16) received biological therapy. The
mean summary scores and multi-item scores at follow-up for
those patients compared to the rest are shown in Fig. 6. UC
patients receiving biological therapy scored lower for MCS
and the following items: VT, SF, RE, and MH, while UC
patients undergoing surgery scored lower for PCS and the
following items: RP, GH, VT, SF and MH (p b 0.01). UC
patients undergoing surgery did not improve in any summary
or multi-item score during follow-up, while patients treated
with biological therapy improved in RP, BP, GH, and PCS
(data not shown). CD patients needing surgery improved all
scores with the exception of PF and RE, while CD patients
treated with biologicals improved all scores but MH and PCS
(data not shown).4. Discussion
We have endeavoured to show that thorough medical and
surgical treatment in a population-based inception cohort of
unselected IBD cases in a community setting improved both
generic and disease-specific HRQoL significantly during the
first year of disease. The majority of CD and UC patients in
both Eastern and Western Europe experienced a more
positive perception of disease-specific HRQoL, though not
of the generic HRQoL. Overall, no differences in generic and
disease-specific HRQoL were found between patients from
Eastern and Western Europe. Patients with UC who had a
worst case scenario and were receiving biological therapy or
undergoing surgery during follow-up had significantly worse
disease-specific and generic QoL at follow-up, when com-
pared to other UC patients.
Up to now only a few studies6,27–29 have assessed the
HRQoL of IBD patients using population-based, unselected
cohorts. Furthermore, in these cohorts HRQoL was assessed
several years after diagnosis. Thus, little is known about the
HRQoL in IBD patients during the initial onset of disease. In
this study we were able to assess HRQoL at diagnosis and
after approximately one year of disease. In terms of generic
HRQoL, both UC and CD patients significantly improved their
SF-12 scores for all items and summary scores, although only
Eastern European UC patients achieved a SF-12 score similar
to or higher than the healthy background population at
follow-up. Previous studies have similarly shown that the
generic HRQoL of CD and UC patients is reduced when
compared to the healthy background population.1,3,30
Conversely, regarding disease-specific HRQoL, the ma-
jority of CD and UC patients experienced a more positive
perception of HRQoL at follow-up. Both surgery31 and
medical treatment32–34 has been shown to improve both
generic and disease-specific HRQoL if disease activity is
reduced. Patients in the EpiCom cohort received early and
aggressive treatment with immunomodulators and reduced
their disease activity during the initial year of disease13;
however, a severe disease course was not associated with a
1035Health-related quality of life improves during one year of medical and surgical treatmentdecrease in SIBDQ score during follow-up nor influenced
changes in HRQoL scores. As degree of disease activity is an
important contributor to patients' perceived HRQoL,35 andTable 1 Patient characteristics of 1079 incident IBD patients fro
Western European centres
CD UC
No. of patients 305 (36%) 437 (52%)
Male 160 (52%) 240 (55%)
Female 145 (48%) 197 (45%)
Age at diagnosis, years 35 (16–89) 39 (15–89)
Time to diagnosis, months 4.6 (0–374) 2.4 (0–255
Smoking status at diagnosis
Never 122 (41%) 233 (55%)
Currently 107 (36%) 35 (8%)
Former smoker 71 (24%) 155 (37%)
Level of education at diagnosis
Academic education 65 (22%) ⁎ 81 (20%) ⁎
Non-academic education 159 (53%) ⁎ 235 (57%) ⁎
Currently attending education 46 (15%) ⁎ 48 (12%) ⁎
No education 28 (9%) ⁎ 46 (11%) ⁎
Employment status at diagnosis
Employed 155 (52%) 225 (54%)
Self-employed 17 (6%) 29 (7%)
Unemployed 45 (15%) 42 (10%)
Student 47 (16%) 54 (13%)
Retired 35 (12%) 68 (16%)
Extra-intestinal manifestations at diagnosis
None 266 (86%) 391 (89%)
Skin 6 (2%) 8 (2%)
Eyes 4 (1%) 6 (1%)
Joints 28 (9%) 31 (7%)
Primary sclerosing
Cholangitis (PSC) 1 (0%) 1 (0%)
Pancreatitis 2 (1%) 0 (0%)
Other 4 (1%) 4 (1%)
Disease extent at diagnosis
E1: Proctitis 85 (19%)
E2: Left-sided 185 (42%)
E3: Extensive colitis 167 (38%)
Disease location at diagnosis
L1: Terminal ileum 87 (29%)
L2: Colon 83 (28%)
L3: Terminal ileum + colon 70 (23%)
L4: Upper GI 22 (7%)
L1 + L4 19 (6%)
L2 + L4 7 (2%)
L3 + L4 13 (4%)
Disease behaviour at diagnosis
B1: non-stricturing, non-penetrating 184 (60%)
B2: stricturing 60 (20%)
B3: penetrating 28 (9%)
B1p: B1 + perianal 14 (5%)
B2p: B2 + perianal 3 (1%)since mucosal healing in IBD patients is associated with
achieving a good HRQoL independently of the type of
medical treatment,36 it is possible that treatment choicesm the EpiCom-cohort.
Eastern European centres
IBDU CD UC IBDU
96 (11%) 97 (40%) 138 (57%) 6 (2%)
47 (49%) 56 (58%) 77 (56%) 4 (67%)
49 (51%) 41 (42%) 61 (44%) 2 (33%)
39 (17–77) 31 (15–78) 36 (18–81) 30 (20–34)
) 2.4 (0–362) 3.4 (0–125) 2.2 (0–240) 2.7 (0–38)
45 (49%) 35 (36%) 76 (55%) 4 (67%)
14 (15%) 36 (38%) 14 (10%) 2 (33%)
33 (36%) 25 (26%) 48 (35%) 0 (0%)
16 (18%) 14 (15%) 38 (28%) 0 (0%)
48 (53%) 51 (53%) 66 (48%) 6 (100%)
7 (8%) 26 (27%) 27 (20%) 0 (0%)
20 (22%) 5 (5%) 7 (5%) 0 (0%)
51 (55%) 47 (49%) 76 (55%) 5 (83%)
6 (6%) 6 (6%) 5 (4%) 0 (0%)
11 (12%) 14 (15%) 9 (7%) 1 (17%)
10 (11%) 20 (21%) 22 (16%) 0 (0%)
15 (16%) 9 (9%) 26 (19%) 0 (0%)
82 (84%) 82 (82%) 120 (86%) 5 (83%)
4 (4%) 2 (2%) 1 (1%) 0 (0%)
3 (3%) 2 (2%) 1 (1%) 0 (0%)
7 (7%) 12 (12%) 13 (9%) 1 (17%)
0 (0%) 0 (0%) 2 (1%) 0 (0%)
0 (0%) 0 (0%) 2 (1%) 0 (0%)
2 (2%) 2 (2%) 1 (1%) 0 (0%)
26 (19%)
64 (46%)
48 (35%)
37 (39%)
19 (20%)
23 (24%)
2 (2%)
5 (5%)
3 (3%)
7 (7%)
66 (68%)
18 (19%)
5 (5%)
1 (1%)
0 (0%)
(continued on next page)
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Table 1 (continued)
Western European centres Eastern European centres
CD UC IBDU CD UC IBDU
B3p: B3 + perianal 16 (5%) 7 (7%)
Highest treatment step reached during follow-up
0: No treatment 7 (2%) ⁎ 3 (1%) 0 (0%) 0 (0%) 1 (1%) 0 (0%)
1: 5-ASA 37 (12%) ⁎ 214 (49%) 45 (47%) 27 (28%) 85 (62%) 4 (67%)
2: GCS 48 (16%) ⁎ 117 (27%) 27 (28%) 24 (25%) 33 (24%) 1 (17%)
3: Immunomodulators 104 (34%) ⁎ 69 (16%) 11 (11%) 31 (32%) 16 (12%) 1 (17%)
4: Biological therapy 63 (21%) ⁎ 21 (5%) 10 (10%) 5 (5%) 1 (1%) 0 (0%)
5: Surgery 46 (15%) ⁎ 13 (3%) 3 (3%) 10 (10%) 2 (1%) 0 (0%)
⁎ Difference between geographic regions, p b 0.05.
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 made in this cohort were appropriate in terms of reducing
disease activity and achieving mucosal healing.
Given the short observation period of the first 12 months of
disease, it is not surprising that only disease-specific HRQoL
normalized during follow-up whereas generic HRQoL, with the
exception of Eastern European UC patients, remained below
the healthy background population. Generic HRQoL measure-
ments capture the full impact of an individual's disease and
allow for comparisons across patients, diseases and different
ages, however often do not necessarily include items of
particular relevance for a given disease and lack of sensitivity
to detect change over time in groups of patients with specific
diseases.1,37 Disease-specific HRQoL measurements on the
other hand assess specific issues impairing patients' health
status and reflect treatment effects better and are more
responsive to treatment interventions, such as those experi-
enced by patients in the EpiCom cohort. The IBD diagnosis is
still new for these patients and while HRQoL may seem
improved when only asked about a single group of dimensions,
e.g. disease specific items, when asked to consider their state
of health from a more general point of view it may need more
time for these patients to normalize their HRQoL perception.
In this study neither treatment with glucocorticosteroids
(alone or in combination) nor treatment with thiopurines
was associated with a worse disease-specific HRQoL for CD
or UC patients. HRQoL has in previous studies beenTable 2 Mean scores (SD) for the Short Inflammatory Bowel Dise
Diagnosis
CD UC IBDU
Western Europe
D1: Bowel 13.6 (4.3) 14.7 (4.2) b 14.9 (4.
D2: Emotional 13.3 (4.6) 14.4 (4.3) b 14.0 (4.
D3: Systemic 8.6 (3.2) 9.5 (3.0) 9.9 (2.
D4: Social 8.9 (4.1) 10.1 (3.9) b 10.6 (3.
Total score 44.9 (13.6) 48.8 (12.9) b 49.9 (12
Eastern Europe
D1: Bowel 14.4 (4.4) 13.6 (3.9) 18.0 (1.
D2: Emotional 12.9 (4.0) 12.8 (4.4) 14.0 (1.
D3: Systemic 8.7 (2.9) 9.1 (2.9) 11.0 (2.
D4: Social 8.8 (4.2) 8.9 (4.1) 12.7 (2.
Total score 45.3 (12.7) 44.9 (12.8) 55.7 (4.
a Difference in the mean score between time of diagnosis and follow
b Difference in the mean score between regions, p b 0.05.negatively associated with corticosteroid treatment6,27,28,30
reflecting either a continued or worsening disease activity
or corticosteroid-related side effects. Furthermore, in
population-based inception cohorts the use of thiopurines
was associated with a deterioration of disease-specific
HRQoL in CD patients6 at five years of follow-up. Due to
the short disease duration the impact of an underlying more
severe disease course may need a longer follow-up to be
proven.
More Western European patients received a biological
therapy during follow-up without any regional differences in
perceived HRQoL. Improvement of disease-specific HRQoL by
biological therapy has been demonstrated in several
placebo-controlled trials with highly selected IBD patients
with long disease duration.33,34 In this unselected cohort
disease-specific and generic HRQoL of CD patients receiving
biological therapy improved significantly during follow-up and
reached normal SIBDQ scores. In contrast, UC patients
receiving biological agents did not significantly improve
HRQoL scores and had, in fact, worse HRQoL scores when
compared to the rest. The same findings weremade in terms of
surgery (resections and colectomies) as UC patients undergoing
surgery at this early stage of disease despite significant
improvement had significantly lower disease-specific and
generic HRQoL scores at follow-up when compared to UC
patients not undergoing surgery. However, the median time toase Questionnaire.
Follow-up
CD UC IBDU
4) 16.3 (3.6) a 16.9 (3.5) a 16.6 (3.4) a
8) 15.5 (4.0) a 15.9 (4.0) a 16.1 (3.9) a
7) 10.3 (2.7) a,b 10.7 (2.8) a,b 10.2 (3.2) b
6) 11.1 (3.4) a 11.9 (3.0) a 11.7 (2.9) a
.3) 53.6 (11.3) a 55.7 (11.0) a 54.9 (11.0) a
7) 17.1 (3.3) a 17.5 (3.4) a 17.7 (2.9)
0) 15.2 (3.3) a 16.1 (3.2) a 16.2 (1.8)
6) 11.2 (2.2) a 11.5 (2.3) a 12.3 (1.0)
3) 11.5 (3.3) a 11.9 (2.6) a 12.7 (1.6)
5) 55.3 (10.5) a 57.4 (9.6) a 58.8 (6.4)
-up, p b 0.05.
016
Figure 1 Proportion of patients with good (SIBDQ score N50)
disease-specific health-related quality of life at diagnosis and
follow-up in an unselected IBD cohort.
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 surgery and rescue therapywith biological agentswas short and
close to the follow-up assessment. Thus the impact of the
intervention on patients' HRQoL might not have had enough
time to become evident in UC patients.
Disease phenotype for CD patients did not have an impact
on whether patients achieved a good disease-specific HRQoL
or not. A possible reason for this could be the low proportion
of patients with stricturing or penetrating disease, however
this finding is in line with other studies.29,38 In UC more
severe disease extent was associated with not achieving a
good HRQoL at follow-up. One could speculate that more
extensive UC led to more aggressive therapy, such as
immunosuppressives, which in this subgroup of patients led
to a poorer HRQoL.
While most patients experienced significant improve-
ments in HRQoL during the follow-up period, the question
about the degree of change required to be clinically
significant has to our knowledge only been addressed for
the SIBDQ, where a change in SIBDQ score of ≥9.3 points has
been suggested to be clinically significant.19 On this premise
only Eastern European patients exhibited a clinically relevantFigure 2 Mean Short Inflammatory Bowel Disease Questionnaire (
1 year FU in Eastern and Western Europe.improvement in disease specific HRQoL over time aswell as CD
patients undergoing surgery or receiving biologicals as well as
UC patients colectomised during follow-up. Further studies
investigating the correlation of changes in HRQoL scores and
e.g. disease activity are warranted, and whether this regional
difference in time will disappear with longer follow-up or will
in fact persist, the five and ten year follow-up of the EpiCom
cohort will hopefully answer.
Some limitations in this study need to be taken into
consideration. First, a subset of patients did not give
consent to fill out the questionnaires. These patients,
however, did not differ from those giving consent in terms
of socio-demographic characteristics. Furthermore, not all
patients filled out questionnaires at both the time of
diagnosis and follow-up and unfortunately it was not
possible to resend the questionnaire in order to secure full
data inclusion. Also, the large margin regarding time of
completion of the questionnaires might influence the
results since some patients will have had longer and/or
different treatment than others. In addition, the method of
administering the questionnaires was not entirely consis-
tent. Depending on the patients' educational level, whether
local translations of the questionnaires were available, and
according to local logistical factors, the questionnaires
were either interview-administered by the physician or
self-administered by the patients. But all data was com-
pleted by trained personnel. Results could be biased
according to how the questionnaire was administered,
since patients might not have given sincere answers on a
face-to-face. However, for IBDQ at least, this has been
shown not to affect the scores significantly.39 Also,
comparing SF-12 scores against the same healthy population
(general U.S. population), rather than to country-specific
norms, has only been shown to be a valid method in Western
European countries.23,24 The distribution of patients is
skewed as the majority of patients were diagnosed in
Western European centres. This is to be expected from this
inception cohort since most participating Eastern European
centres are low-incidence areas.40 As the patient popula-
tions from Eastern andWestern Europe were similar in termsSIBDQ) scores in the 2010 IBD inception cohort at diagnosis and
, 2016
Figure 3 Short Inflammatory Bowel Disease Questionnaire (SIBDQ) scores in patients undergoing surgery or receiving biological
therapy during follow-up.
Figure 4 Change in SIBDQ score during follow-up depending on baseline SIBDQ score in a European inception cohort of IBD patients.
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Table 3 Factors influencing positive changes in health-related quality of life at follow-up.
SIBDQ SF-12, MCS SF-12, PCS
CD UC CD UC CD UC
Coming from Eastern Europe – – P = 0.049 – – –
Age b40 years at diagnosis – – – – – p = 0.032
Being a non-smoker – p b 0.001 – – – –
Having an education – – – – p b 0.001 –
No extra-intestinal manifestations – – – – p = 0.045 –
No biological therapy during follow-up – p b 0.001 p = 0.037 p b 0.001 – –
No surgery during follow-up – p b 0.05 – – – –
Shorter disease extent in UC – P = 0.025 – – – –
PCS, physical component summary score; MCS, mental component summary score.
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 of socio-economic characteristics, diagnostic procedures
used and time to diagnosis and disease classification,12 we
do not think the disease course being influenced by the region
of origin. Lastly, HRQoL cross-cultural differences and
geographical variations in the perception of health status,
the impact of disease on HRQoL, as well as differences in
healthcare delivery across Eastern and Western Europe may
have influenced the way patients responded to HRQoL
questionnaires.41–43
The strengths of the study are its prospective design and
that the cohort is a population-based inception cohort of
incident IBD patients diagnosed within well-defined geo-
graphic areas and with standardised diagnostic criteria, caseTable 4 Mean scores (SD) for the Short Form 12 questionnaire.
Diagnosis
CD UC IBDU
Western Europe
PF 47.2 (11.8) 49.2 (10.5) b 50.1 (10.0) b
RP 40.9 (13.2) 44.7 (12.0) 44.9 (12.4)
BP 39.0 (14.1) 46.1 (12.4) b 45.3 (11.6)
GH 38.7 (13.0) 42.5 (12.1) b 40.7 (11.0) b
VT 43.6 (12.6) 45.2 (11.7) 45.3 (11.1)
SF 41.4 (12.6) 44.5 (11.6) 45.8 (10.8)
RE 40.8 (15.0) 43.4 (13.7) 43.4 (13.8)
MH 45.8 (11.5) 45.6 (11.4) 46.5 (11.0)
PCS 42.3 (11.3) 46.9 (9.9) b 46.1 (9.7)
MCS 43.1 (12.0) 43.7 (11.6) 43.8 (11.9)
Eastern Europe
PF 48.2 (11.4) 46.4 (11.1) 56.5 (0.0)
RP 42.5 (12.1) 43.6 (11.3) 49.5 (13.3)
BP 41.6 (11.7) 42.6 (12.0) 50.6 (5.9)
GH 40.1 (12.3) 39.3 (11.6) 54.1 (8.7)
VT 46.5 (11.8) 47.3 (11.5) 54.5 (11.6)
SF 43.1 (13.3) 43.4 (12.3) 46.5 (10.1)
RE 41.0 (12.9) 42.1 (12.0) 37.4 (17.1)
MH 43.1 (12.6) 43.2 (11.6) 50.3 (12.7)
PCS 44.7 (10.2) 44.3 (10.3) 56.3 (7.0)
MCS 42.2 (12.7) 43.5 (11.0) 43.3 (17.4)
PF, physical functioning; VT, vitality; RP, role-physical; SF, social func
MH, mental health; PCS, physical component summary score; MCS, me
a Difference in the mean score between time of diagnosis and follow
b Difference in the mean score between regions, p b 0.05.ascertainment methods, and intervals of follow-up visits and
recorded data. As such, the patients are unselected and
represent the broad spectrum of disease severity from mild,
indolent to severe cases. Treatment choices and their
potential impact on HRQoL are the results of community
effectiveness of treatment guidelines amongst physicians.
In conclusion, basedonaEuropeanprospectivepopulation-based
inception cohort of unselected IBD patients, generic and
disease-specific HRQoL tends to improve during the first
year of disease subsequent to diagnosis. The majority of CD
and UC patients in both Eastern and Western Europe
experienced a more positive perception of disease-specific
HRQoL; however this was not the case for generic HRQoL.Follow-up
CD UC IBDU
50.0 (10.6) a 51.1 (9.6) a 49.5 (10.0) b
46.8 (10.6) a,b 48.9 (9.4) a 47.6 (9.8)
47.1 (11.4) a 50.0 (10.5) a,b 47.4 (11.1)
42.7 (11.2) a,b 44.0 (11.6) 43.8 (11.0)
49.1 (12.0) a,b 49.9 (11.3) a,b 49.5 (10.5) a
47.4 (10.6) a 48.1 (10.3) a 49.0 (9.5)
45.4 (12.1) a 46.8 (11.2) a 46.6 (11.2)
48.4 (11.3) a 48.5 (11.4) a,b 49.5 (10.6)
47.6 (9.7) a 49.3 (9.0) a 47.5 (10.1)
47.1 (11.7) a 47.5 (11.3) a 48.7 (10.8) a
51.7 (8.3) a 51.3 (8.3) a 55.0 (3.5)
49.7 (8.7) a 49.4 (9.5) a 51.8 (8.5)
48.4 (11.7) a 52.1 (8.9) a 50.6 (10.5)
45.5 (10.2) a 44.9 (10.3) a 47.6 (7.0)
52.4 (11.3) a 52.3 (10.8) a 56.1 (9.9)
49.9 (8.9) a 49.5 (9.3) a 53.2 (5.2)
47.4 (11.9) a 46.9 (11.1) a 45.8 (9.0)
49.7 (11.5) a 51.3 (9.6) a 53.4 (9.8)
49.4 (7.0) a 50.2 (7.3) a 52.6 (6.0)
49.5 (11.3) a 50.2 (9.7) a 50.7 (6.4)
tioning; BP, bodily pain; RE, role-emotional; GH, general health;
ntal component summary score.
-up, p b 0.05.
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Figure 5 Mean summary scores for the Short Form 12
questionnaire at diagnosis and follow-up in Crohn's disease
(CD) and ulcerative colitis (UC) patients.
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 While biological therapy significantly improved and nor-
malized HRQoL in CD patients, UC patients in need of
aggressive therapy with surgery or biological agents had a
significantly lower HRQoL at follow-up than other patients
in this study.Figure 6 Short Form 12 questionnaire scores in patients
undergoing surgery or receiving biological therapy during follow-up.
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